Sanjiv S. Gangaram-Panday, PhD, on Esophageal Cancer: Active Surveillance vs Standard Surgery After Neoadjuvant Chemoradiotherapy

October 28, 2026

Sanjiv S. Gangaram-Panday, PhD, of Erasmus University, presents 5-year outcomes from the Surgery As Needed for Oesophageal Cancer (SANO) trial. The study previously demonstrated that active surveillance is noninferior to standard surgery in terms of 2-year overall survival in patients with a complete clinical response after neoadjuvant chemoradiotherapy; active surveillance also resulted in improved quality of life (Abstract LBA78). 

Related Content